Mizoribine (MZ) inhibits the differentiation and proliferation of helper T and B cells after antigen recognition by suppressing the purine biosynthesis pathway and nucleic acid synthesis. MZ has been used in kidney transplantation, but distinct data are unavailable for islet transplantation. The present study investigated the efficacy of MZ for islet xenotransplantation. Immunosuppressive effects of MZ were determined by mixed lymphocyte reaction (MLR) assay in vitro. Toxicities for Wistar rat islets were determined by adenosine triphosphate (ATP) contents of islets during 3-day culture and stimulation index in response to glucose after culture. Immunosuppressive effects in vivo were tested in a Wistar-to-B6 islet xenotransplantation model. MZ was administered continuously for 28 days subcutaneously or intramuscularly. MZ inhibited MLR response by approximately 50% at 0.1 µg/ml. ATP contents decreased with MZ >100 µg/ml, while stimulation index was maintained. Continuous infusion of MZ at 10 mg/kg maintained blood concentrations at 0.13-0.19 µg/ml, while intramuscular injection of MZ at 100 mg/kg/day (peak 520 µg/ml at 1 h postinjection) resulted in below measurable levels (<0.03 µg/ml) within 24 h. Graft survival was significantly prolonged following continuous infusion of 10 mg/kg/day compared to controls (31.0 ± 9.5 vs. 13.2 ± 5.2 days; p = 0.002). Furthermore, animals with intramuscular injection at doses of 3.2, 10, or 100 mg/kg/day showed significantly longer graft survival (20.0 ± 7.5, 22.0 ± 7.31, and 24.5 ± 8.1 days, respectively; p < 0.05 each). Histological examination showed significant suppression of lymphocyte infiltration by MZ administration. MZ showed immunosuppressive effects in an experimental islet xenotransplantation model without adverse effects on endocrine function of islet grafts. 535 536 YAMASHITA ET AL.
INTRODUCTION
progression of renal dysfunction is one of the major complications in type 1 diabetes mellitus (1, 3, 9, 19, 21, 23, 28, 30, 31) . Islet transplantation has spread worldwide since the successes of the Edmonton protocol (26, 28, 30) . How-Mizoribine (MZ) is an imidazole class nucleoside that was isolated from culture medium of the mold ever, results from long-term follow-up have shown that most recipients revert to some level of insulin use, Eupencillium brefeldianum M-2166 (15, 18) . The drug has been found to inhibit both humoral and cellular although islet transplantation can relieve glucose instability and problems with hypoglycemia by improving immunity by suppressing DNA synthesis through the inhibition of purine biosynthesis via antagonistic block-endogenous insulin secretion (28, 31) . Further progress in improving long-term results for islet transplantation ing of inosine monophosphate (IMP) dehydrogenase (IMPDH) (15, 18) . Micophenolate mofetil (MMF), in the will thus require immunosuppressive protocols (40, 41) . Sirolimus and tacrolimus were used in the Edmonton same class of drugs, has been used for immunosuppression following islet transplantation in cases requiring protocol, but have various adverse effects, including islet toxicity and suppression of both islet revasculariza-discontinuation of calcineurin inhibitors or sirolimus due to adverse effects (5) . However, clinical studies of MMF tion and islet regeneration (1, 3, 19, 21, 23) . Immunosuppressive drugs used for islet transplantation should not have shown a high incidence of leucopenia and diarrhea (2, 33) . In contrast, MZ has fewer adverse effects, such as only display minimal toxicity to transplanted islets, but also limited deleterious effects on renal function, since hematological and gastrointestinal events, in clinical usage (36) . MZ has been widely used in human kidney trans-Mixed Lymphocyte Reaction (MLR) plantation, particularly in Japan (37). This evidence led us MLR was performed as previously described (38) . to examine the effects of MZ in islet transplantation.
Briefly, irradiated (2000 rads, cesium source) donor A shortage of donor organs represents another serious strain (Wistar rat) splenocytes were used as stimulators. problem in islet transplantation, as each recipient cur-A total of 8 × 10 5 cells isolated from the spleen of the rently needs two to three transplantations under present recipient C57BL/6 were used as responders. Naive methods (28, 30, 31) . Use of xenoislet graft is one of the C57BL/6 splenocytes were used as controls. Responder best options to resolve this problem (26). Recently, cells and an equal number of irradiated stimulator cells modification of α-galactosyl antigen expression in were cultured with 0, 0.1, 0 B6 mice were used as recipients for measurement of MATERIALS AND METHODS blood MZ concentrations after intramuscular or continuous subcutaneous injection of MZ. Blood samples were Animals collected from the right ventricle of the heart at 1, 2, Male C57BL/6 (B6; H-2b) mice and Wistar rats, and 4 h after injection of the drug intramuscularly at approximately 8 weeks old, were purchased from Clea doses of 1, 10, or 100 mg/kg/day, or at 3, 7, and 14 Japan (Osaka, Japan). Wistar rats were used as donors days after starting continuous administration of the drug and B6 mice as recipients. Diabetes was induced by subcutaneously at doses of 1, 10, 20, 30, or 60 mg/kg/ intraperitoneal injection of streptozotocin (STZ) (Sigma day. Blood MZ concentration was measured by high-Chemical, St. Louis, MO) at 250 mg/kg body weight, performance liquid chromatography (12). and was diagnosed when nonfasting blood glucose levels increased to >400 mg/dl on two consecutive mea-Assessment of Islet Graft Function In Vitro surements. This experimental protocol was approved by
The insulin secretory capacities in response to low the Ethics Review Committee for Animal Experimenta-(50 mg/dl) and high (300 mg/dl) glucose, as glucose tion at Fukushima Medical University. stimulation index, were evaluated using a modification of the method reported by Ricordi et al. after culture for Islet Isolation and Transplantation 3 days following isolation with or without MZ (27) . Doses of MZ were 0, 0.5, 1.0, 10, or 100 µg/ml. Briefly, Islet isolation and transplantation were performed as described previously (7) . Briefly, we injected Hank's after 6 h of culture in RPMI-1640 solution at 37°C under 5% CO 2 and 95% air in a humidified atmosphere, five balanced salt solution (Nissui, Tokyo, Japan) containing 2 mg/ml of collagenase (collagenase S-1; Nitta Gelatin, sets of 20 islets of 150-200 µm in diameter were handpicked. These islets were placed in a 12-well transwell Osaka, Japan) into the common bile duct. The distended pancreas was removed and incubated at 37°C. Collagen-microplate (Corning Transwell 3403, pore size 12 µm; Corning, Lowell, MA, USA) with 50 mg/dl of glucose ase-digested islets were purified by centrifugation on gradients composed of three different Ficoll (type 400, RPMI-1640 and 0.1% fetal calf serum (FCS) at 37°C for 60 min for stabilization. After preincubation, the Sigma) densities (1.120, 1.090, and 1.050). After centrifugation, the distinct layer of islets was collected and transwell was placed in the second well cluster containing 3.3 mM glucose RPMI-1640 and 0.1% FCS and washed. Diabetic B6 mice acting as recipients were anesthetized with diethyl ether (Wako Pure Chemicals, incubated for 60 min. The transwell was then placed in the third well cluster containing 300 mg/dl glucose for Osaka, Japan). The left kidney was exposed through a lumbar incision under sterile conditions, and 350-400 60 min. Supernatants of the second and third well clusters were immediately collected and frozen at −20°C islets were transplanted into the left renal subcapsular space of recipients.
until assessment. Insulin content was measured using ultrasensitive rat insulin enzyme-linked immunosorbent (Progen Bitechnik, Heidelberg, Germany). Cross-reactivity to mice of these antibodies has already been estab-assay kits (Morinaga, Kanagawa, Japan). Stimulation index was calculated by dividing insulin secretion at lished by the supplying companies.
To detect CD4 and CD8 cells, cryostat sections were high glucose by that at low glucose.
air dried, fixed in acetone for 10 min, and hydrated in
Evaluation of MZ Toxicity
Tris-buffed saline (pH 7.4) for 10 min. After fixation in formol calcium solution for 1 min, sections were washed Islets were cultured for 3 days in the presence of MZ at concentrations of 0, 1.0, 10.0, 100, or 1,000 µl/ml, three times with phosphate-buffered saline (PBS) and incubated overnight with biotin-conjugated rat anti-and adenosine triphosphate (ATP) levels of 10 islet equivalent (IEQ) islets were measured. ATP contents of mouse CD8a monoclonal antibody (BD PharMingen, San Diego, CA, USA) or biotin-conjugated rat anti-islets were measured using the bioluminescent enzymatic cycling assay as previously reported (14). Briefly, mouse CD4 monoclonal antibody (BD PharMingen) at 4°C. After washing with PBS, slides were incubated 33 µl of 0.5 N HClO 4 was added to the well containing islets with 300 µl of culture medium, and then this solu-with peroxidase-conjugated streptavidin for 30 min. Slides were washed with PBS and fixed with 1% glutar-tion was frozen at −80°C until assayed. Next, 20 µl of sample and 80 µl of Tris buffer were mixed, then 100 aldehyde solution for 3 min before staining for peroxidase activity with 3,3′-diaminobenzidine tetrahydrochloride µl of each bioluminescence reagent [firefly luciferase alone; firefly luciferase with pyruvate kinase (PK); or (DAB; Wako Pure Chemicals) in 500 mM Cary, NC, USA). Graft survival-prolonging effects were In the Wistar rat to B6 mice combination, recipient analyzed using the Kaplan-Meier method and log-rank mice were divided into groups with MZ (MZ group) or test. Differences between groups in ATP levels and without MZ (control group). In the MZ group, MZ was stimulation index (SI) were examined for statistical sigadministered continuously at a dose of 10 mg/kg for 28 nificance using Student's t-test with Bonferroni correcdays subcutaneously using an osmotic pump (0.2 ml, tion. All values of p < 0.05 were considered indicative Alzet 2001; Durect, Cupertino, CA, USA) implanted of a significant statistical difference. subcutaneously in the back of the mouse at the time of transplantation or intramuscularly at doses of 1.0, 3.2, 10, RESULTS or 100 mg/kg/day on the medial aspect of the thigh once
In Vitro MLR Assay daily (29) . The pump was exchanged using the same pro-MLR assay was used to determine the immunosupcedure after 14 days and was removed on day 28.
pressive dose of MZ in vitro ( Fig. 1 ). Maximum MLR Nonfasting blood glucose levels of each recipient responses were obtained on days 3 and 4 in this xenocomwere measured daily to monitor islet graft survival durbination. The lymphoproliferative reaction was inhibited ing the first 3 weeks and then every other day. Graft by MZ in a concentration-dependent manner. The concenrejection was defined by the day that blood glucose level tration of MZ at which the reaction was inhibited by exceeded 300 mg/dl on 2 successive days.
approximately 50% was 0.1 µg/ml, while concentrations >0.5 µg/ml completely inhibited the reaction.
Histological Examination of Grafted Tissue
Grafts were removed at 7 days after transplantation Pharmacokinetic Profile of MZ for histological studies in the control group and continuous infusion of MZ at a dose of 10 mg/kg/day. Speci-MZ concentrations in blood after intramuscular administration at doses of 1, 10, and 100 mg/kg/day mens containing the transplantation site were fixed in 10% buffered formalin, embedded in paraffin, and cut were 0.2, 1.5, and 500 µg/ml at 1 h, respectively (n = 3 in each group). In animals given 100 mg/kg/day of MZ, into 4.5-µm-thick sections. Sections were stained with hematoxylin and eosin (H&E) or stained immunohisto-these concentrations rapidly decreased to 2.3 µg/ml after 4 h and were below the measurable level after 24 h. logically with rabbit anti-human insulin polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
Blood concentrations in animals given intramuscular MZ at 1.0 or 10 mg/kg/day decreased more rapidly and rabbit anti-human glucagon polyclonal antibody below the measurable level within 4 h after administra-Nonfasting Blood Glucose Levels and Graft Survival After Islet Transplantation tion ( Fig. 2A) .
In animals continuously infused with 1.0, 10, 20, 30, Nonfasting blood glucose levels in animals given or 60 mg/kg/day, blood MZ concentrations on day 3 islet xenograft without MZ treatment (Fig. 4A ) or aniafter starting administration were <0.03 (below the meamals with MZ treatments, continuously at a dose of 10 surable limit): 0.17 ± 0.01, 0.20 ± 0.04, 1.00 ± 0.48, and mg/kg for 28 days subcutaneously (Fig. 4B) or intra-1.20 ± 0.42 µg/ml, respectively (n = 3 in each group). muscularly at doses of 1.0 ( Fig. 4C ), 3.2 (Fig. 4D ), 10 These concentrations remained at measurable levels ( Fig. 4E ), or 100 ( Fig. 4F ) mg/kg/day were restored to until 14 days after starting MZ, with the exception of 1.0 normal within a couple of days following transplantamg/kg/day. However, mice that received MZ at doses tion, indicating no toxic effects of MZ on glucose of 20, 30, and 60 mg/kg/day developed signs of severe metabolism. Animals given continuous infusion of 10 anorexia, dehydration, and hypoglycemia, and died at mg/kg/day of MZ showed significantly longer graft sur-7-13 days after starting MZ (Fig. 2B) .
vival compared to controls (control, 12.0 ± 0.9 days; continuous infusion of 10 mg/kg/day MZ, 31.0 ± 3.4 Evaluation of MZ Toxicity on Islet ATP Content days; p = 0.002) ( Fig. 5B ). Furthermore, animals with intramuscular injection at doses of 3.2, 10, and 100 mg/ ATP contents of islets cultured for 3 days with 0, 1.0, kg/day showed significantly longer graft survival at 20.0 10.0, 100, or 1,000 µl/ml of MZ were 25.0 ± 1.2, 28.2 ± ± 3.4, 22.0 ± 3.1, and 24.5 ± 4.5 days, respectively (p < 2.6, 22.3 ± 1.3, 15.2 ± 1.5, and 13.8 ± 1.0 pmol/10 IEQ, 0.01) ( Fig. 5D-F) . However, intramuscular administrarespectively (Fig. 3A) . Groups of islets cultured with tion at a dose of 1.0 mg/kg/day failed to prolong graft 100 or 1,000 µl/ml of MZ showed significantly lower survival (Fig. 5C ). ATP levels than islets without MZ (p < 0.001). These concentrations were thus considered as toxic levels.
Histological Examination Histologically, marked infiltration of inflammatory Assessment of Islet Graft Function In Vitro cells was observed at transplanted sites of grafts in the control group, whereas relatively fewer inflammatory Glucose stimulation index after 3 days culture in the presence of MZ at doses of 0, 0.5, 1.0, 10, and 100 µg/ cells were noted in MZ groups at 7 days after xenotransplantation. The microscopic structure of islets was main-ml were 2.3 ± 0.3, 2.4 ± 0.6, 2.4 ± 0.1, 2.7 ± 0.8, and 2.0 ± 0.4, respectively (Fig. 3B) . No significant differences tained relatively well in MZ groups (Fig. 6B ).
Immunohistochemical study using anti-insulin antibody were noted between MZ-treated islets compared with untreated islets, indicating no immediate adverse effects and anti-glucagon antibody revealed that many of the respective positive cells were observed in the MZ group of this drug with the doses and duration examined here on insulin secretory capacity in response to glucose.
compared with the control group (Fig. 6C-F) .
Immunostaining of anti-CD4 and anti-CD8 revealed effects, including leukopenia and diarrhea (13,36,37). However, MZ has not been applied for islet transplanta-that marked CD4-and CD8 + lymphocyte infiltration around transplanted islets was suppressed in the MZ groups in xen-tion experimentally or clinically. To the best of our knowledge, this is the first investigation of the effects orecipients compared to controls ( Fig. 6G-J) .
of MZ using in vitro assays and an islet xenotransplanta-DISCUSSION tion model. Our results from MLR showed that immunosuppressive effects of MZ were evident at concentrations MZ is an immunosuppressive drug showing antiproliferative effects by the blockade of IMPDH activity ≥0.1 µl/ml. The immunosuppressive effects of MZ as evaluated by MLR in humans have been reported to be (15, 18) . This drug is widely used in clinical renal transplantation in Japan with a significant effect in prevent-obtained with the same concentration used in our study (34). Furthermore, insulin secretory capacities were not ing acute rejection and reducing the incidence of adverse suppressed with these concentrations. However, ATP day in hamster-to-rat heart transplantation had only marginal effects on prolongation of graft survival (22) . MZ content in islets significantly decreased with 100 and 1,000 µl/ml of MZ, suggesting some toxic effects at was administered by gastric instillation in that study, but no data were available for blood concentration. Our these doses. For this study, we therefore selected a target concentration for MZ of >0.1 µl/ml but <100 µl/ml. results demonstrate that MZ is effective either by continuous infusion or daily intramuscular injection for sur-In this rat-to-mouse xenotransplantation model, prolongation of graft survival was achieved by continuous vival benefit in islet xenotransplantation.
Histological study of the xenografting model using subcutaneous administration of MZ at a dose of 10 mg/ kg/day, with blood concentrations of MZ maintained Wistar rats to B6 mice revealed suppression of infiltration by CD4 + and CD8 + cells at transplanted islet sites in within target levels during treatment. Furthermore, animals with intramuscular injection at doses of 3.2, 10, or the subcapsular space of the kidney. We have previously reported that islet xenografts in the same combination 100 mg/kg/day showed significantly longer graft survival than untreated animals. Shimmura et al. reported
using Wistar-to-B6 were rejected in a CD4-dependent pathway, since administration of anti-CD4 antibody sig-that prolongation of graft survival in allocombination using a heart transplantation model was achieved when nificantly prolonged islet graft survival in this combination (8). MZ reportedly has an immunosuppressive the drug was administered intramuscularly at >80 mg/ kg/day (32). Our results indicate that prolongation of effect in suppressing IL-2 production by CD4 + T cells (35) . The CD4 pathway could thus be dependently sup-graft survival for islet xenotransplantation is achieved using a lower dose, unlike solid organ allotransplanta-pressed by MZ treatment, which might be a leading cause of prolonged survival of islet xenografts. tion. Of note, prolongation was possible with both continuous infusion and intramuscular injection with an Histological study revealed that infiltration of CD4 + and CD8 + cells around transplanted islets was sup-immediate peak concentration, although toxicity was more profound when given continuously. Murase et al.
pressed by MZ administration. The mechanism underlying immunosuppression by MZ is the inhibition of DNA reported that MZ monotherapy at a dose of 7.5 mg/kg/ synthesis in proliferative lymphocytes following antigen IMP-binding site of IMPDH. Also, the strain of Candida albicans that shows MPA-resistant IMPDH is reportedly presentation (4, 15, 18) . A similar mechanism has been reported for MMF, which is already used in clinical islet sensitive to MZ, since MPA and MZ have different mechanisms of IMPDH inhibition (16) . MZ also shows transplantation in combination with other immunosuppressive drugs (5) . Recently, details have been reported other immunosuppressive activities, including inhibition of B-cell function and antibody production (11,25). Our of the mechanism underlying inhibition of IMPDH activity by MZ and mycophenolic acid (MPA), the results thus indicate that MZ could be one candidate for islet xenotransplantation in combination with other active form of MMF (6) . MPA inhibits the conversion of IMP to xanthine monophosphate (XMP) by binding immunosuppressive drugs. Although the Edmonton protocol has been spread to the nicotinamide adenine dinucleotide (NAD)-binding site of IMPDH and trapping E-XMP, an intermediate of worldwide, discontinuation of the immunosuppressive drugs, tacrolimus or rapamycin, represents one of the IMP conversion to XMP. In contrast, MZ monophosphate inhibits IMPDH activity by binding to the main problems, since these drugs have many adverse effects, such as β-cell toxicity, aphtha, and renal dys-and a 13.9-38.4% incidence of diarrhea (2,5,33). Reports have described 18.1-36.3% of patients who function (1, 3, 19, 21, 23) . In clinical situations, MMF has been used instead of these drugs, but clinical studies of received organ transplantation under MMF requiring reduction or discontinuation of MMF administration due MMF have shown a 12.1-37.8% incidence of leukopenia to adverse events (2, 33 
